Cleidocranial dysplasia (CCD; MIM 119600) is an autosomal dominant skeletal dysplasia characterised by hypopalstic and/or aplastic clavicles, midface hypoplasia, absent or delayed closure of cranial sutures, moderately short stature, delayed eruption of permanent dentition and supernumerary teeth. The molecular pathogenesis can be explained in about two-thirds of CCD patients by haploinsufficiency of the RUNX2 gene. In our current study, we identified a novel and rare variant of the RUNX2 gene (c.181_189dupGCGGCGGCT) in a Japanese patient with phenotypic features of CCD. The insertion led an alanine tripeptide expansion (+3Ala) in the polyalanine tract. To date, a RUNX2 variant with alanine decapeptide expansion (+10Ala) is the only example of a causative variant of RUNX2 with polyalanine tract expansion to be reported, whilst RUNX2 (+1Ala) has been isolated from the healthy population. Thus, precise analyses of the RUNX2 (+3Ala) variant were needed to clarify whether the tripeptide expanded RUNX2 is a second disease-causing mutant with alanine tract expansion. We therefore investigated the biochemical properties of the mutant RUNX2 (+3Ala), which contains 20 alanine residues in the polyalanine tract. When transfected in COS7 cells, RUNX2 (+3Ala) formed intracellular ubiquitinated aggregates after 24 h, and exerted a dominant negative effect in vitro. At 24 h after gene transfection, whereas slight reduction was observed in RUNX2 (+10Ala), all of these mutants significantly activated osteoblast-specific element-2, a cis-acting sequence in the promoter of the RUNX2 target gene osteocalcin. The aggregation growth of RUNX2 (+3Ala) was clearly lower and slower than that of RUNX2 (+10Ala). Furthermore, we investigated several other RUNX2 variants with various alanine tract lengths, and found that the threshold for aggregation may be RUNX2 (+3Ala). We conclude that RUNX2 (+3Ala) is the cause of CCD in our current case, and that the accumulation of intracellular aggregates in vitro is related to the length of the alanine tract.
Introduction
Cleidocranial dysplasia (CCD; MIM 119600) is an autosomal dominant skeletal dysplasia characterised by hypoplastic and/or aplastic clavicles, midface hypoplasia, persistently open or delayed closure of cranial sutures, a moderately short stature, delayed eruption of permanent dentition and supernumerary teeth (1-3). The phenotype manifests over a broad spectrum of severity, from mildly affected individuals with mere dental abnormalities to severely affected patients with generalised osteoporosis. Moreover, even within a family, considerable phenotypic variation has been reported (2, 4) .
It has been demonstrated previously that CCD is caused by a haploinsufficiency in the Runt-related Transcription Factor 2 gene (RUNX2; MIM 600211), also known as Core Binding Factor A1 (CBFA1), located on chromosome 6p21 (1) . The product of the RUNX2 gene is part of a transcription factor complex that directs the differentiation of mesenchymal precursor cells toward mature osteoblasts (1, 5) . Inactivation of Runx2/Cbfa1 in mice leads to perinatal death, with complete absence of bone formation including no osteoblast differentiation and ossification (5, 6) . Heterozygous Runx2/Cbfa1 mutant mice display all the pathological features of human CCD (7, 8) . RUNX2 includes several functional domains. The Runt domain is a 128-amino acid polypeptide motif originally described in the Drosophila Runt gene, which is responsible for independently mediating DNA binding and protein heterodimerisation (9) . The nuclear localisation signal (NLS) was identified on the C-terminal border of the Runt domain (10) . In addition, RUNX2 contains an N-terminal stretch of consecutive polyglutamine and polyalanine repeats (Q/A domain), and a C-terminal proline/serine/ threonine-rich (PST) activation domain (11, 12) . The Q/A domain consists of a continuous 23 glutamine residues (polyglutamine) and 17 alanine residues (polyalanine), and forms β sheets that are resistant to chemical denaturation and enzymatic degradation under physiological conditions in vitro (13) .
Many types of RUNX2 mutations have been reported as the causes of CCD, such as missense, nonsense, frame shift and splice mutations, as well as large chromosomal deletions and translocations (14) . Most mutations impair the Runt domain, which is crucial for the biological function of the RUNX family of transcription factors (15) . Exceptionally rare variants of RUNX2 with an expansion of the polyalanine (1), or polyglutamine tract (16) have been reported as causes of CCD. These mutant RUNX2 genes contain an in-frame 30-bp duplication (leading from 17 to 27 alanine residues: +10Ala), or an in-frame 12-bp duplication (leading from 23 to 27 glutamine residues), respectively. In addition, a nucleotide polymorphism with 18 alanine residues in the polyalanine tracts (+1Ala) of RUNX2 was isolated from normal individuals in the Danish population (14) .
Polyalanine domains are one of the most common structures in transcription factors, and in-frame duplications in this region are frequently associated with congenital developmental disorders in humans, such as HOXD13 in synpolydactyly, HOXA13 in hand-foot-genital syndrome, FOXL2 in blepharophimosis syndrome, PHOX2B in congenital central hypoventilation syndrome, ZIC2 in holoprosencephaly, PABPN1 in oculopharyngeal muscular dystrophy, ARX in X-linked mental retardation and SOX3 in X-linked mental retardation with growth hormone deficiency (13, 17) . Generally, the length of the normal polyalanine tracts in these transcription factors is 14-20 alanine residues, and the pathogenic expansions comprise 18-29 alanine residues (13) . In addition, other reports have suggested that a pathogenicity threshold could be traced at 19 alanine residues (13, 18) . Molecules with polyalanine expansion aggregate as intracellular inclusions with ubiquitination for degradation via the proteasome, leading to cell death (13, 19) . However, the molecular pathology of polyalanine expansion largely remains obscure, in particular for CCD.
In our current study, we identified a novel mutation (c.181_189dupGCGGCGGCT, leading from 17 to 20 polyalanine tracts: +3Ala) of the RUNX2 gene in a Japanese patient with CCD, and performed functional analyses to reveal the pathogenicity of the mutant product. Moreover, we performed further experiments to estimate the threshold of aggregation of RUNX2 with various alanine-repeat lengths.
Material and methods

Mutation detection
After informed consent was obtained from the patients, genomic DNA samples were extracted from their peripheral blood leukocytes using a PAXgene Kit (Qiagen, Valencia, CA, USA). Exons 0-7 of the RUNX2 gene were amplified by PCR under standard conditions. The primers used for genomic PCR amplification and sequencing have been described elsewhere (20) . Mutation analysis of the complete coding sequence of the RUNX2 gene and exon-intron boundaries was performed using the Big Dye Termination Reaction Kit on an ABI PRISM 370 DNA sequencer (Applied Biosystems, Foster City, CA, USA). Once a mutation was detected, the PCR product harbouring this mutation was cloned into the pGEM-T Easy Vector (Promega, Madison, WI, USA).
Plasmid construction and mutagenesis
The full-length human RUNX2 cDNA was cloned into the pCMV6-XL5 expression vector (OriGene Technologies, Rockville, MD, USA) and pCMV6-XL5-RUNX2 was generated, incorporating a FLAG epitope tag at the C-terminus of RUNX2. To eliminate one of two PstI restriction enzyme sites without amino acid substitution, C > G transversion at the nucleotide position c.102 in the human RUNX2 cDNA was carried out using mega PCR primers. In vitro site-directed mutagenesis was then performed using the inverse PCR method to generate the RUNX2 polyalanine variants; +1Ala (18 alanine tract: normal individuals; 14), +2Ala (19 alanine tract: unreported), +3Ala (20 alanine tract: this study), +10Ala (27 alanine tract: reported as a causative variant for CCD; 1). The obtained fragments were ligated at the Bgl II and Pst I sites of the pCMV6-XL5 plasmid with/without FLAG tag. The integrity of all the PCR constructs was confirmed by sequencing. The p6OSE2-Luciferase reporter plasmid (containing six tandem copies of osteoblast-specific element-2) was kindly provided by Dr Komori (Nagasaki University; 21).
Cell culture, transient transfection and immunofluorescence
COS7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) foetal bovine serum at 37°C in an atmosphere of 5% CO 2 . Transient transfections were carried out using Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA). At 24, 48 and 60 h after transfection, the cells were fixed with 3.75% (w/v) paraformaldehyde/phosphate-buffered saline (PBS) and permeabilised with 0.2% (v/v) Triton X-100/PBS, and then incubated with a mouse anti-FLAG monoclonal antibody (1:1000 dilution; Sigma, St. Louis, MO, USA), and a rabbit antipolyubiquitin antibody (1:400 dilution; Abcam, Cambridge, UK) overnight at 4°C. For immunofluorescence, an antimouse IgG-biotinylated antibody was used (1:1000 dilution; Vector Lab, Burlingame, CA, USA), followed by incubation with antirabbit IgG-Cy3 (1:400 dilution; Jackson ImmunoResearch, West Grove, PA, USA), Alexa-488-conjugated streptavidin (1:1000 dilution; Molecular Probes, Carlsbad, CA, USA), and 4′,6-Diamidino-2-phenylindole (DAPI; 1 μg/ml) for 1 h at room temperature.
Microscopy observation
The cells were washed three times with PBS, and visualised under an Olympus BH-2 microscope (Olympus, Tokyo, Japan). Images were captured using the Photoshop Elements 11 software (Adobe, San Jose, CA, USA) and then analysed to calculate the nuclear localisation score, as previously described, with minor modifications (22) . Briefly, the cells were scored for the subcellular localisation of RUNX2 variant proteins as follows: 4, nuclear fluorescence much greater than cytoplasmic fluorescence; 3, nuclear fluorescence greater than cytoplasmic fluorescence; 2, nuclear fluorescence equal to cytoplasmic fluorescence; 1, nuclear fluorescence less than cytoplasmic fluorescence and 0, nuclear fluorescence much less than cytoplasmic fluorescence. The nuclear localisation scores represented the mean ± standard error of the mean. More than 100 cells were counted in at least two independent experiments. According to a previous report (23) , the aggregation percentage was assessed; briefly, a total of 200 FLAG-positive COS-7 cells were selected, and the proportion of cells with aggregates was counted.
DNA transfection and luciferase reporter assays
DNA transfections and luciferase assays were performed according to previously reported methods, with minor modifications (24, 25) . Briefly, transfection experiments were carried out in HEK293 cells at 40-50% confluence using Lipofectamine 2000 (Invitrogen) in accordance with the manufacturer's instructions. Each transfection was performed in triplicate in a poly-l-lysine coated 24-well plate (Iwaki glass, Tokyo, Japan), with 400 ng of reporter plasmid p6OSE2-luc, which contains six tandem copies of the osteoblastspecific element-2, the RUNX2-binding promoter sequence, 10 or 100 ng of RUNX2 expression vectors and 2 ng of pRL-TK, an expression vector for sea pansy (Renilla reniformis) luciferase used as an internal control. Cells were incubated for 24 h after transfection. Firefly luciferase and Renilla luciferase activities were measured in a luminometer using the Dual Luciferase Reporter assay system kit (Promega, Madison, WI, USA). Cells were lysed in 100 µl of passive lysis buffer with agitation for 30 min at room temperature, and 10 µl aliquots were used for measurements. The luciferase activity elicited by the RUNX2-binding-promoter constructs was normalised for variations in transfection efficiency using Renilla luciferase as an internal standard. Statistical analysis was performed using the Welch's t-test. A P < 0.05 was considered to indicate a statistically significant difference between experimental and wild-type groups.
Results
Patient information and mutation analysis
A 29-year-old Japanese woman diagnosed as CCD was referred to the Department of Maxillofacial Surgery Aichi-Gakuin University School of Dentistry to restore a primary failure of tooth eruption. She was the first child of young, healthy, non-consanguineous parents. She showed severe short stature (−4.2 SD), vertebral malformations as scoliosis, midface hypoplasia, sloping shoulders and mild brachydactyly. Radiologic examinations and three-dimensional computer tomography demonstrated hypoplasia of the maxilla, failure in closure of the cranial sutures as zygomaticomaxillary suture, multiple impacted tooth and very mild hypoplasia of both clavicles ( Figure 1A) . These clinical and radiologic findings indicated a diagnosis of CCD phenotype (26) . ( Figure 1B) . Unfortunately, genetic material from other family members could not be obtained due to a lack of cooperation.
Polyalanine-expanded mutant RUNX2 (+3Ala) forms intracellular aggregates in COS7 cells
To investigate the pathological role of the RUNX2 polyalanine tract expansion in CCD, we determined whether the polyalanine expansion mutant RUNX2 (+3Ala, 20 polyalanine) formed intracellular aggregations (Figure 2A) . At 12 h after transfection, the RUNX2 mutant protein was found to be exclusively located in the nuclei. After 24 h, the protein started to form small aggregates in the periphery of the nuclei and was less abundant in the nucleus. The aggregates become slightly larger with time and, finally, the protein was predominately excluded from the nuclei.
Characteristics of the polyalanine-expanded mutant RUNX2
To determine whether +3Ala RUNX2 aggregates were ubiquitinated, we carried out double staining for anti-FLAG and antiubiquitin antibodies at 48 h after transfection. Aggregations of the +3Ala RUNX2 were positively immunostained with an antiubiquitin antibody ( Figure 2B ). This result indicates that the aggregates that formed because of polyalanine expansion are associated with ubiquitindependent degradation. Next, to investigate whether the mutant protein also caused wild RUNX2 protein to aggregate, FLAG tagged wild-type RUNX2 was coexpressed with +3Ala mutated RUNX2 in Cos-7 cells. Immunolocalisation of the FLAG tagged wild protein was detected in the nuclei ( Figure 2C ). As these perinuclear aggregates also included wild-type RUNX2, we speculated that this might lead to delayed intramembranous ossification and defective chondrocyte maturation in vivo. This finding can also partly explain the dominant characteristics of the polyalanine expansion mutation.
Correlation between expanded alanine mutation and intracellular aggregation
To determine the pathogenic threshold of polyalanine expansion in RUNX2, we generated mutant constructs of RUNX2 in the expression plasmid with +1, +3, +10 alanine residue expansion and analyzed the transcriptional activities of these variants on the regulatory regions of OSE2, which consists of six tandem copies of osteoblast-specific element-2 (25). This transactivation experiment showed that the +1Ala and +3Ala mutants retained almost normal transcription activity, whereas +10Ala mutants had significantly lower activity ( Figure 3A) . Next, to identify any correlation between the lengths of the polyalanine stretch and severity of the intracellular aggregation, we analysed the intracellular aggregates formed by proteins with various polyalanine lengths, including the +2Ala variant. Reduction of the nuclear localisation score indicated a misfolded protein exported from the nuclei, because of the intact NLS in these polyalanine-expanded mutants (10, 27) . The results showed that the +3Ala expansion reduced the nuclear localisation score at 24 h compared with the wild-type, whereas there was no difference in this regard between +1Ala, +2Ala and wild-type. Furthermore the +10Ala score was reduced to a larger extent than that of +3Ala within 60 h ( Figure 3C ), and aggregates of the +3Ala RUNX2 mutant formed more rapidly than those of the wild-type. Whilst the peaks of the ratio of cells with +1Ala and +2Ala aggregations was observed at 60 h, +10Ala aggregates appeared more rapidly and were larger than those in +3Ala-expressing cells ( Figure 3B and D). These findings suggested that the polyalanine expansion threshold of aggregation could be +3Ala, and that the alanine tract length shows a certain correlation with intracellular aggregation.
Discussion
In our current study, we identified a novel alanine-expanded mutation of RUNX2 in a Japanese sporadic CCD patient with a characteristic phenotype for this disorder ( Figure 1A ). This heterozygous mutation, induced by a c.181_189dupGCGGCGGCT insertion, resulted in +3Ala expansion (from 17 to 20 alanine residues in the polyalanine tract ( Figure 1B) . The +3Ala expansion, compared with +10Ala, showed a slight but plain accumulation of intracellular aggregates with ubiquitination ( Figure 2A and B) . In addition, the mutant gene product led to a dominant-negative effect by sequestering the wild-type RUNX2 protein in the aggregates ( Figure 2C ). Although robust transcriptional activity of the mutant proteins was detected at lower expression levels 24 h after gene transfection, an inhibitory effect was observed at higher expression levels of RUNX2 (+10Ala; Figure 3A ). These observations suggest that these RUNX2 mutants may form an unstable but functional molecular complex in the nuclei, which have sufficient transcriptional activity before forming the aggregates. Finally, we demonstrated the correlation between the length of the alanine expansion and the severity of the intracellular aggregate formation in vitro ( Figure 3B-D) . Alanine expansion was first identified in the HOXD13 gene as the disease-causing mechanism in synpolydactyly syndrome (SPD) (28) . Similar mutations have since been identified in other eight autosomal dominant or X-linked disorders. Eight of the nine human congenital diseases known to be caused by polyalanine tract expansions, excluding PABPNl (involved in mRNA polyadenylation), are related to gene mutations within transcription factors. In most cases, congenital malformations are observed in the skeletal or nervous system. Whereas the lengths of the glutamine stretches causing polyglutamine diseases have a definite correlation with the age of onset and severity, such a relationship is unclear in polyalanine diseases. Since most reported pathogenic expansions in the polyalanine tract involve a limited extent of alanine residues, it has been postulated that a common molecular mechanism is shared among them (29) . Previous clinical studies have reported that the length of the polyalanine tract expansion in the HOXD13 gene correlates with the severity and penetrance of the SPD phenotype; for instance, individuals with short repeats, i.e. +7Ala, present considerable intra-familial and also-individual variability and low penetrance, whereas those with long expansions, i.e. +10Ala and more, have a more severe phenotype with complete penetrance (30) . Conversely, such correlations are unclear for the heterozygous PHOX2B mutations in congenital central hypoventilation syndrome (31) . Whereas a case with RUNX2 +10Ala mutation was described with minor craniofacial features of CCD and brachydactyly in a previous report (1), our current +3Ala case presented the characteristic phenotype of CCD with severe short stature, tooth anomalies, mild brachydactyly and mild clavicular hypoplasia. Thus, our present findings did not reveal any clear correlation between the length of alanine tract and clinical phenotype.
We speculated that the phenotypic variations of CCD might derive from the genetic background rather than from the difference in the RUNX2 polyalanine length. Cytoplasmic aggregations mediate, at least in part, the pathogenicity of polyalanine expansion diseases (18) . Moreover, the molecular structures of the expanded alanine tract proteins are resistant to proteolytic degradation, and thus insoluble aggregates accumulate, despite the ubiquitination of these proteins. When unfolded proteins develop and exceed the cell degradative capacity, the continued accumulation of misfolded proteins eventually induces Expression plasmids for Runx2 variants were transiently transfected into COS-7 cells followed by staining with anti-FLAG antibody (green) and DAPI (blue). Representative fluorescent micrographs are shown. Scale bar: 20 μm. Whereas a robust nuclear localisation was detected in the cells expressing wild-type RUNX2, RUNX2 (+1Ala) and RUNX2 (+2Ala), cytoplasmic aggregations were observed in the cells expressing RUNX2 (+3Ala) and RUNX2 (+10Ala). Wild, wildtype RUNX2; +1Ala, RUNX2 (+1Ala); RUNX2 (+2Ala), +3Ala; RUNX2 (+3Ala), +3Ala; RUNX2 (+10Ala), +10Ala. apoptosis (31) . FLAG tagged wild-type RUNX2 aggregate was detected in the cells expressing RUNX2 (+3) ( Figure 2C ). This result indicates a dominant negative effect of polyalanine expanded RUNX2 (+3). It has been demonstrated that polyalanine expanded HOXD13 induces molecular aggregation of wild-type RUNX2, and RUNX2 (+10) also induces molecular aggregation of wild-type HOXD13 in vitro (32) . Our observation confirms the idea that expanded alanine repeats could interact with other polyalanine-containing proteins, which Mundlos et al. (32) discussed in the previous report. Then, we investigated the time course of aggregate formation of the mutant RUNX2 products of various polyalanine tract lengths, as described previously Hoxd13 mutants. (27) In the early stage, the +3Ala protein located in the nucleus at 12 h after gene transfection, and then small aggregated proteins including wild-type RUNX2 could be found in the cytoplasm that expanded continuously and finally accumulated in the periphery of the nucleus at 24 and 48 h, with ubiquitination ( Figure 2A-C) . Finally, sufficient aggregation leads to the mislocalisation of the protein in the cytoplasm at 60 h. Thus, the defect of the nuclear RUNX2 protein affects osteoblast differentiation and leads to disease. Our current analyses indicate the existence of a relationship between polyalanine tract length and the cytoplasmic aggregation of RUNX2, because the aggregations of +10Ala appeared earlier and grew faster than those of +3Ala. A previous report revealed that a progressive decrease of PHOX2A transcriptional activity in this context is strictly dependent on the alanine tract length expansion (33) . In our current analyses, a slight reduction in the transcriptional activity of +10Ala was detected in a dose-dependent manner at 24 h after RUNX2 gene transfection ( Figure 3A ). This result indicates that these mutant proteins are biologically active prior to aggregate formation, and suggests that the velocity of cytoplasmic aggregate formation depends on the concentration of RUNX2 mutant protein in the nucleus, as well as on the alanine tract lengths.
In conclusion, we have identified a novel heterozygous mutation of RUNX2 with a three-alanine residue expansion in the polyalanine tract in a Japanese sporadic CCD patient. Subsequent in vitro experiments provided evidence that this short expansion induced cytoplasmic aggregate formation, and thus affected the biological function of RUNX2. Moreover, we revealed the relationship between the polyalanine tract length and the time course of cytoplasmic aggregate formation of RUNX2 mutants in vitro. However, the definitive effects on other related transcriptional factors due to aggregate formation of RUNX2 are still unclear. Further studies will be needed to elucidate the precise molecular mechanisms underlying the impact of RUNX2 with alanine tract expansion on the pathophysiology of CCD.
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